Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
NCT ID: NCT00870103
Last Updated: 2010-03-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
64 participants
INTERVENTIONAL
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery
NCT01515826
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients
NCT01859702
A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery
NCT03634852
PRO-232 in Patients Subjected to Cataract Surgery
NCT07305987
A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery
NCT03687931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vigadexa eye drops
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
1 drop every 6 hours into the study eye
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
1 drop every 6 hours into the study eye
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to sign an informed consent and complete all required visits
* intends to have a cataract extraction surgery followed by implantation of a posterior chamber Intraocular lens (IOL)
* Intraocular Pressure (IOP) ≦ 20 millimeters mercury (mmHg)
Exclusion Criteria
* use of ocular anti-infectious during the study and within 30 days prior to the enrollment, secondary implantation or replacement of IOL in the study eye
* use of steroid during the study or within 14 days prior to enrollment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alcon Research Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alcon Call Center
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RM-08-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.